Evidence that podia formation and adhesion to the CSC niche plays a role in HNSCC CD44+ cells may improve the understanding of these interactions and offer insight into new strategies for cancer-directed therapy in HNSCC using small molecule agonists or antagonists of SDF-1 (10). This evidence concerns the gene CXCL12 and cancer.